Literature DB >> 12488500

CD40 ligation and phagocytosis differently affect the differentiation of monocytes into dendritic cells.

Michelle Rosenzwajg1, Frédéric Jourquin, Ludovic Tailleux, Jean Claude Gluckman.   

Abstract

That monocytes can differentiate into macrophages or dendritic cells (DCs) makes them an essential link between innate and adaptive immunity. However, little is known about how interactions with pathogens or T cells influence monocyte engagement toward DCs. We approached this point in cultures where granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin (IL)-4 induced monocytes to differentiate into immature DCs. Activating monocytes with soluble CD40 ligand (CD40L) led to accelerated differentiation toward mature CD83(+) DCs with up-regulated human leukocyte antigen-DR, costimulatory molecules and CD116 (GM-CSF receptor), and down-regulation of molecules involved in antigen capture. Monocytes primed by phagocytosis of antibody-opsonized, killed Escherichia coli differentiated into DCs with an immature phenotype, whereas Zymosan priming yielded active DCs with an intermediate phenotype. Accordingly, DCs obtained from cultures with CD40L or after Zymosan priming had a decreased capacity to endocytose dextran, but only DCs cultured with CD40L had increased capacity to stimulate allogeneic T cells. DCs obtained after E. coli or Zymosan priming of monocytes produced high levels of proinflammatory tumor necrosis factor alpha and IL-6 as well as of regulatory IL-10, but they produced IL-12p70 only after secondary CD40 ligation. Thus, CD40 ligation on monocytes accelerates the maturation of DCs in the presence of GM-CSF/IL-4, whereas phagocytosis of different microorganisms does not alter and even facilitates their potential to differentiate into immature or active DCs, the maturation of which can be completed upon CD40 ligation. In vivo, such differences may correspond to DCs with different trafficking and T helper cell-stimulating capacities that could differently affect induction of adaptive immune responses to infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12488500

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  6 in total

Review 1.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 2.  Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.

Authors:  Meredith L Stone; Gregory L Beatty
Journal:  Pharmacol Ther       Date:  2019-05-31       Impact factor: 12.310

Review 3.  Innate immune cells in breast cancer--from villains to heroes?

Authors:  Tim Kees; Mikala Egeblad
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-07-26       Impact factor: 2.673

4.  Bacterial probiotic modulation of dendritic cells.

Authors:  Maureen Drakes; Thomas Blanchard; Steven Czinn
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

5.  Modulation of neuronal differentiation by CD40 isoforms.

Authors:  Huayu Hou; Demian Obregon; Deyan Lou; Jared Ehrhart; Frank Fernandez; Archie Silver; Jun Tan
Journal:  Biochem Biophys Res Commun       Date:  2008-02-27       Impact factor: 3.575

6.  TNF-α promotes IFN-γ-induced CD40 expression and antigen process in Myb-transformed hematological cells.

Authors:  Wenyi Gu; Jiezhong Chen; Lei Yang; Kong-Nan Zhao
Journal:  ScientificWorldJournal       Date:  2012-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.